Advances in FL

CE / CME

Current and Emerging Therapeutic Advances in Follicular Lymphoma: A Class in Session

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: March 06, 2023

Expiration: March 05, 2024

Activity

Progress
1
Course Completed
References

  1. Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management. Am J Haematol. 2022;97:1638-1651.
  2. Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow up. Ann Oncol. 2021;32:298-308.
  3. Casulo C, Dixon JG, Le-Rademacher J, et al. Validation of POD24 as a robust early clinical endpoint of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139:1684-1693.
  4. Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379:934-947.
  5. Morschhauser F, Nastoupil L, Feugier P, et al. Six-year results from RELEVANCE: lenalidomide plus rituximab (R2) versus rituximab-chemotherapy followed by rituximab maintenance in untreated advanced follicular lymphoma. J Clin Oncol. 2022;40:3239-3245.
  6. Tazemetostat [prescribing information]. Cambridge, MA: Epizyme, Inc.; 2020.
  7. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: B-cell lymphomas. v.2.2023. nccn.org. Accessed February 13, 2023.
  8. Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23:91-103.
  9. Neelapu SS, Chavez J, Sehgal AR, et al. 3-year follow-up analysis of ZUMA-5: a phase II study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). Presented at: 64th ASH Annual Meeting and Exposition; December 10-13, 2022. Abstract 4660.
  10. Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase II ELARA trial. Nat Med. 2022;28:325-332.
  11. Dreyling M, Dickinson M, Lopez JM, et al. Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed/refractory follicular lymphoma (r/r FL) treated with tisagenlecleucel in the ELARA trial. Presented at: 64th ASH Annual Meeting and Exposition; December 10-13, 2022. Abstract 608.
  12. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625-638.
  13. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: management of immunotherapy-related toxicities. v.1.2022. nccn.org. Accessed February 13, 2023.
  14. Mosunetuzumab-axgb [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2022.
  15. Carrasco-Padilla C, Hernaiz-Esteban A, Alvarez-Vallina L, et al. Bispecific antibody format and the organization of immunological synapses in T cell-redirecting strategies for cancer immunotherapy. Pharmaceutics. 2023;15:132.
  16. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase II study. Lancet Oncol. 2022;23:1055-1065.
  17. Bartlett NL, Sehn LH, Matasar M, et al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ³2 prior therapies: updated results from a pivotal phase II study. Presented at: 64th ASH Annual Meeting and Exposition; December 10-13, 2022. Abstract 610.
  18. Kim TM, Tazner M, Cho SG, et al. Odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) grade 1-3a: results from a prespecified analysis of the pivotal phase II study ELM-2. Presented at: 64th ASH Annual Meeting and Exposition; December 10-13, 2022. Abstract 949.
  19. Falchi L, Abrisqueta P, Nijland M, et al. Subcutaneous epcoritamab with rituximab + lenalidomide in patients with relapsed or refractory follicular lymphoma: phase 1/2 trial update. Presented at: 64th ASH Annual Meeting and Exposition; December 10-13, 2022. Abstract 609.
  20. Falchi L, Leslie LA, Belada D, et al. Subcutaneous epcoritamab in combination with rituximab + lenalidomide (R2) for first-line treatment of follicular lymphoma: initial results from phase 1/2 trial. Presented at: 64th ASH Annual Meeting and Exposition; December 10-13, 2022. Abstract 611.
  21. Leonard JP, Jung SH, Johnson J, et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015;33:3635-3640.
  22. Bödor C, Grosmann V, Popov N, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013;122:3165-3168.
  23. Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21:1433-42.
  24. Batlevi C, Salles G, Park SI, et al. Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma: phase 1b results of Symphony-1. Presented at: 64th ASH Annual Meeting and Exposition; December 10-13, 2022. Abstract 954.
  25. Dreyling M, Santoro A, Mollica L, et al. Long-term safety and efficacy of the P13K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol. 2022;95:362-371.
  26. Copanlisib [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2022.